Advertisement

High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study

      Abstract

      Long-term trials have demonstrated the continued efficacy of interferon (IFN) beta treatment in patients with relapsing–remitting (RR) multiple sclerosis (MS) during prolonged administration.
      The objective of the work was to evaluate the effects of reducing IFN beta administration frequency and total weekly dose in patients with RR MS who have achieved clinical and MRI disease activity stabilization during long-term IFN beta-1b treatment. Prospective 1-year follow-up of 27 RR MS patients on long-term 250 μg every other day (standard dose) IFN beta-1b treatment were randomized either to gradually reduce dose to 30 μg once-a-week IFN beta-1a (13 patients), or to continue on IFN beta-1b standard dose (14 patients).
      We found significant differences in the two group of patients. In the group of patients continuously treated with IFN beta-1b standard dose, 79% remained relapse free compared to 23% in the group receiving once-weekly IFN beta-1a (p=0.006). The number of patients without new PD/T2 lesions was higher in the group of patients continuously treated with IFN beta-1b standard dose (77%) compared to the once-weekly IFN beta-1a group (23%) (p=0.04). IFN beta is a long-term treatment for MS. The reduction of IFN beta-1b administration frequency and dose is not advisable even in patients free from clinical and MRI disease activity for many years.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jacobs L.D
        • Cookfair D.L
        • Rudick R.A
        • Herndon R.M
        • Richert J.R
        • Salazar A.M
        • et al.
        Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.
        Ann. Neurol. 1996; 39: 285-294
        • The IFNβ Multiple Sclerosis Study Group
        Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.
        Neurology. 1993; 43: 655-661
        • The PRISMS study Group
        Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing–remitting multiple sclerosis.
        Lancet. 1998; 352: 1498-1504
        • Kurtzke J.F
        Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • The IFNβ Multiple Sclerosis Study Group
        • University of British Columbia MS/MRI Analysis Group
        Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial.
        Neurology. 1995; 45: 177-185
        • Stone L.A
        • Frank J.A
        • Albert P.S
        • Bash C
        • Smith M.E
        • Maloni H
        • et al.
        The effect of interferon-β on blood–brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis.
        Ann. Neurol. 1995; 37: 611-619
        • Stone L.A
        • Frank J.A
        • Albert P.S
        • Bash C
        • Calabresi P.A
        • Maloni H
        • et al.
        Characterization of MRI response to treatment with interferon beta-1b: contrast enhancing MRI lesion frequency as primary outcome measures.
        Neurology. 1997; 49: 862-869
        • Miller D.H
        • Albert P.S
        • Barkhof F
        • Francis G
        • Frank J.A
        • Hodgkinson S
        • et al.
        Guidelines for use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis.
        Ann. Neurol. 1996; 39: 6-16
        • Miller A
        • Lanir N
        • Shapiro S
        • Revel M
        • Honigman S
        • Kinarty A
        • et al.
        Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis and other autoimmune diseases.
        J. Neuroimmunol. 1996; 64: 151-161
        • Rudick R.A
        • Simonian M.A
        • Alam J.A
        • Campion M
        • Scaramucci J.O
        • Jones W
        • et al.
        Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
        Neurology. 1998; 50: 1266-1272
        • Durelli L
        • Verdun E
        • Barbero P
        • Bergui M
        • Versino E
        • Grezzi A
        • et al.
        Every-other-day interferon beta-1b versus once-a-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN).
        Lancet. 2001; 359: 1453-1460
        • Panitch H
        • et al.
        • for the EVIDENCE (EVidence of Interferon Dose–response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research group
        Randomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE Trial.
        Neurology. 2002; 59: 1496-1506
        • Poser C.M
        • Paty D.W
        • Scheinberg L
        • McDonald W.I
        • Davis F.A
        • Ebers G.C
        • et al.
        New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
        Ann. Neurol. 1983; 13: 227-231
        • Antonelli G
        • Bagnato F
        • Pozzilli C
        • Simeoni E
        • Battistelli S
        • Correnti M
        • et al.
        Development of neutralizing antibodies in patients with relapsing remitting multiple sclerosis treated with IFN beta-1a.
        J. Interferon Cytokine Res. 1998; 18: 345-350
        • Goodkin D.E
        • Ross J.S
        • Medendorp S.V
        • Konecsni J
        • Rudick R.A
        Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence or measurement artifact?.
        Arch. Neurol. 1992; 49: 261-263
        • Filippi M
        • Gawne-Cain M.L
        • Gasperini C
        • vanWaesberghe J.H
        • Grimaud J
        • Barkhof F
        • et al.
        Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.
        Neurology. 1998; 50: 238-244
        • Filippi M
        • Rovaris M
        • Campi A
        • Pereira C
        • Comi G
        Semiautomated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads.
        Acta Neurol. Scand. 1996; 93: 30-34
        • Khan O.A
        • Hebel J.R
        Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing–remitting multiple sclerosis.
        Ann. Neurol. 1998; 44: 138-139
      1. Evidence of interferonβ-1a dose response in relapsing–remitting MS. The OWIMS Study. The Once Weekly Interferon for MS Study Group.
        Neurology. 1999; 53: 679-686
        • Rice G.P.A
        • Incorvaia A.B
        • Munari L
        Interferon in relapsing–remitting multiple sclerosis (Cochrane review).
        in: The Cochrane Library, Issue 4. Update Software, Oxford2001: 853-863
        • Stuve O
        • Dooley N.P
        • Uhm J.H
        • Antel J.P
        • Francis G.S
        • Williams G
        • et al.
        Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.
        Ann. Neurol. 1996; 40: 853-863
        • Leppert D
        • Waubant E
        • Burk M.R
        • Oksenberg J.R
        • Hauser S.L
        Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T-cells: a possible mechanism for treatment efficacy in multiple sclerosis.
        Ann. Neurol. 1996; 40: 846-852
        • Alam J
        • Goelez S
        • Rioux P
        • Scaramucci J
        • Jones W
        • McAllister A
        • et al.
        Comparative pharmacodynamics of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers.
        Pharm. Res. 1997; 14: 546-549
        • Sturzebecher S
        • Maibauer R
        • Heuner A
        • Beckmann K
        • Aufdembrinke B
        Pharmacodynamic comparison of single doses of IFNβ-1a and IFNβ-1b in healthy volunteers.
        J. Interferon Cytokine Res. 1999; 19: 1257-1264
        • Ravandi F
        • Estrov Z
        • Kurzrock R
        • Breitmeyer J.B
        • Maschek B.J
        • Talpaz M
        A phase I study of recombinant interferon beta in patients with advanced malignant disease.
        Clin. Cancer Res. 1999; 5: 3990-3998
        • Takano S
        • Satomura Y
        • Omata M
        Effects on interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study.
        Gastroenterology. 1994; 107: 805-811
        • Kermode A.G
        • Tofts P.S
        • Thompson A.J
        • MacManus D.G
        • Rudge P
        • Kendall B.E
        • et al.
        Heterogeneity of blood–brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement.
        Neurology. 1990; 40: 229-235
        • McFarland H.F
        • Frank J.A
        • Albert P.S
        • Smith M.E
        • Martin R
        • Harris J.O
        • et al.
        Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
        Ann. Neurol. 1992; 32: 758-766
        • Kappos L
        • Moeri D
        • Radue E.W
        • Schoetzau A
        • Schweikert K
        • Barkhof F
        • et al.
        Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and change in disability or impairment in multiple sclerosis: a meta-analysis.
        Lancet. 1999; 353: 964-969
        • Li D.K
        • Zhao G
        • Paty D.W
        T2 hyperintensities: findings and significance.
        Neuroimaging Clin. N. Am. 2000; 10: 717-738